Search company, investor...

Founded Year



Unattributed VC - II | IPO

Total Raised


Market Cap


Stock Price


About iCAD

iCAD is a global medical technology leader that focuses on innovative cancer detection and therapy solutions. The company offers advanced cancer detection solutions and innovative cancer therapy solutions, providing precise and powerful healthcare solutions designed to optimize operational efficiency, clinician confidence, and patient outcomes. iCAD primarily sells to the healthcare industry, particularly in the areas of cancer detection and treatment. It was founded in 1984 and is based in Nashua, New Hampshire.

Headquarters Location

98 Spit Brook Road Suite 100

Nashua, New Hampshire, 03062,

United States




Expert Collections containing iCAD

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

iCAD is included in 1 Expert Collection, including Conference Exhibitors.


Conference Exhibitors

5,302 items

iCAD Patents

iCAD has filed 26 patents.

The 3 most popular patent topics include:

  • breast cancer
  • breast imaging
  • medical imaging
patents chart

Application Date

Grant Date


Related Topics




Breast cancer, Medical imaging, Image processing, Artificial neural networks, Breast imaging


Application Date


Grant Date



Related Topics

Breast cancer, Medical imaging, Image processing, Artificial neural networks, Breast imaging



Latest iCAD News

iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare

Nov 28, 2023

Nashua, New Hampshire, UNITED STATES Key apps from the iCAD Breast Health Suite are now integrated with GE HealthCare’s new MyBreastAI Suite* AI applications streamline workflow and support clinicians in delivering more personalized breast care, including cancer detection, density assessment, and recommendations NASHUA, N.H., Nov. 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced that key artificial intelligence (AI) powered solutions from iCAD’s ProFound Breast Health Suite are the first applications to be offered in GE HealthCare’s new MyBreastAI Suite* offering. As breast cancer becomes the most commonly diagnosed cancer worldwide, iCAD’s AI solutions are integral to addressing critical issues in breast imaging - such as access, burnout, variability, equity, and cost. GE HealthCare’s MyBreastAI Suite, with iCAD's three key AI-enabled solutions from iCAD, aims to streamline workflow and help clinicians in accelerating breast cancer detection and delivering more personalized and effective breast care. “iCAD has been collaborating with GE HealthCare for more than 20 years and this latest offering is a powerful affirmation of our shared mission to advance breast health,” said Dana Brown, President and CEO of iCAD, Inc. “Our ProFound AI DBT technology is a cornerstone of AI-enabled solutions and is now offered as part of GE HealthCare’s MyBreastAI Suite to seamlessly deploy AI to breast imaging workflow to help enhance the detection and diagnosis of breast cancer while optimizing workflow efficiency to ultimately, help elevate patient care outcomes globally.” MyBreastAI Suite provides an all-in-one platform that can seamlessly deploy AI to breast imaging workflow. The first three AI applications to be offered as part of the initial release include the following solutions from iCAD: ProFound Detection, AI for Digital Breast Tomosynthesis (DBT): A high-performing, deep-learning AI workflow solution that rapidly evaluates 3D mammograms to detect malignant soft tissue densities and calcifications with unrivaled accuracy, 2x enhanced clinical performance compared to other AI platforms1. Providing Lesion Scores and Case Scores, ProFound Detection aids in clinical decision-making, workload prioritization, and could help reduce burnout. SecondLook for 2D Mammography: Utilizes AI to identify potential cancers in 2D mammography, marking suspicious areas promptly and clearly. PowerLook Density Assessment: Automates breast density evaluation, providing an objective, reproducible measure that is crucial for personalized screening recommendations. "Key AI-powered solutions from iCAD’s ProFound Breast Health Suite are the first applications to be integrated with GE HealthCare’s MyBreastAI Suite which is an exciting way to advance our ongoing collaboration to continue deliver breast cancer detection and diagnostic innovation," continued Brown. Clinical studies have demonstrated that the use of iCAD’s ProFound AI solutions can significantly improve reading sensitivity and specificity, as well as reduce reading times, thus enhancing clinical decision support and workflow efficiency for radiologists. Specifically, ProFound AI offers clinically proven time-saving benefits to radiologists, including a reduction of reading time by 52.7%, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8% and reduced unnecessary patient recall rates by 7.2%.2 MyBreastAI Suite, featuring key iCAD AI-enhanced solutions, will be available first in the United States and distributed, installed, and supported by GE HealthCare as part of their Senographe Pristina mammography portfolio. This announcement coincides with GE HealthCare’s and iCAD’s presence at the Radiological Society of North America (RSNA) annual meeting in Chicago as it unveils new research evaluating its ProFound AI in breast cancer risk detection and heart disease. About iCAD, Inc. iCAD, Inc . (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. The ProFound Breast Health Suite is cleared by the U.S. Food & Drug Administration (FDA) and has received CE mark and Health Canada licensing. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, visit . Media Contacts:

iCAD Frequently Asked Questions (FAQ)

  • When was iCAD founded?

    iCAD was founded in 1984.

  • Where is iCAD's headquarters?

    iCAD's headquarters is located at 98 Spit Brook Road, Nashua.

  • What is iCAD's latest funding round?

    iCAD's latest funding round is Unattributed VC - II.

  • How much did iCAD raise?

    iCAD raised a total of $14.73M.

  • Who are the investors of iCAD?

    Investors of iCAD include Iroquois Capital Group, Omicron Capital, Bernay Box, Deephaven Capital Management, Highbridge Capital Management and 3 more.

  • Who are iCAD's competitors?

    Competitors of iCAD include Kheiron Medical Technologies and 3 more.


Compare iCAD to Competitors

ScreenPoint Medical Logo
ScreenPoint Medical

ScreenPoint Medical offers a smart software for improving the results of breast cancer screening. The software reads mammograms like a human reader and supports radiologists by identifying and interpreting potential problem areas on X-ray images. The company was founded in 2014 and is based in Nijmegen, Netherlands. Logo provides an artificial intelligence (AI) based system to identify abnormalities in head computed tomography (CT) scans. It leverages deep learning to diagnose diseases from radiology and pathology imaging and create personalized cancer treatment plans from psychopathology imaging and genome sequences. The company was founded in 2016 and is based in Mumbai, India.


Xylexa is a digital health company that specializes in the development and provision of AI-powered, computer-aided diagnostic platforms. The company's main service is to provide caregivers and radiologists with an automated, accurate, and cost-effective method for interpreting medical images. The primary sectors that Xylexa serves are the healthcare and medical technology industries. It was founded in 2017 and is based in Littleton, Colorado.

Enlitic Logo

Enlitic is a company that focuses on healthcare data management, specifically within the domain of radiology. The company offers solutions that standardize, protect, integrate, and analyze medical imaging data, using artificial intelligence to improve clinical workflows and create a real-world evidence medical image database. Enlitic primarily serves the healthcare industry, with a particular focus on radiologists, PACS administrators, hospital executives, and researchers. It was founded in 2014 and is based in San Francisco, California.

Entelai Logo

Entelai provides artificial intelligence software for medical image analysis in healthcare organizations. It facilitates healthcare and solves patient diagnostic challenges helping doctors and institutions to provide a differentiated service. Its primary care system provides quality consultations at the patient’s reach, when and where needed. The company was founded in 2018 and is based in Buenos Aires, Argentina.

Coreline Soft Logo
Coreline Soft

Coreline Soft develops medical 3D imaging software. Its product offerings include AVIEW, a suite of quantitative analysis software for lung disease powered by a fully automated AI algorithm. The company was founded in 2012 and is based in Seoul, South Korea.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.